Picture of Gerresheimer AG logo

GXI — Gerresheimer AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Germany's Gerresheimer prelim Q3 revenue rises on strong demand for drug delivery devices

Germany's Gerresheimer prelim Q3 revenue rises on strong demand for drug delivery devices


Overview

  • Germany pharma packaging provider's preliminary Q3 revenue rose 8% yr/yr to EUR 605 mln

  • Adjusted EBITDA for Q3 remained stable compared to prior year

  • Revenue growth driven by higher demand for drug delivery devices


Outlook

  • Gerresheimer expects a stronger Q4 2026 with further earnings improvement, in line with guidance

  • Company expects completion of Primary Packaging Plastics business sale in Q1 2027

  • Measures underway to improve capacity utilization and competitiveness in Tubular Glass business


Result Drivers

  • DRUG DELIVERY DEVICES - Co said rising demand for drug delivery devices drove revenue growth in Containment & Delivery Systems division

  • INVENTORY REDUCTION - Co said inventory reductions in Moulded Glass division lowered capacity utilization and negatively impacted adjusted EBITDA

  • DIVISION PERFORMANCE - Co said weaker performance in Tubular Glass Europe and Moulded Glass divisions contributed to lower adjusted EBITDA for 9M period


Company press release: ID:nEQ7M0XGpa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 605 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Gerresheimer AG is €26.90, about 15.7% below its October 29 closing price of €31.90

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Oct 29 - Germany's Wacker Chemie's Q3 core profit nearly doubles on cost cuts; keeps outlook

  • Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook

  • Oct 29 - Merck Q3 profit beats on Keytruda demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Gerresheimer AG

See all news